Table 1:
Participant characteristics (n = 252)
| Mean ± SD or % (n) | |
|---|---|
| Sociodemographic characteristics | |
| Age, years· | 49·7 ± 13·4 |
| Female | 91 (228) |
| Male | 9 (24) |
| Race | |
| Asian | 32 (80) |
| Black | 10 (26) |
| White | 40 (101) |
| Mixed | 3 (8) |
| Other | 14 (36) |
| Hispanic ethnicity | 23 (59) |
| Income below poverty | 12 (29) |
| Education | |
| Less than high school | 5 (12) |
| High school degree | 11 (27) |
| Some college | 15 (38) |
| Associate degree, trade school | 14 (36) |
| College/university degree | 31 (78) |
| Post-graduate, professional | 24 (60) |
| Married | 57 (143) |
| Patient-reported outcomes (PROs) | |
| PROMIS Physical Function | 47·2 ± 9·8 |
| PROMIS Pain Interference | 53·3 ± 9·7 |
| PROMIS Fatigue | 52·9 ± 10·6 |
| PROMIS Sleep Disturbance | 51·2 ± 9·2 |
| NeuroQoL Cognitive Function | 47·3 ± 9·7 |
| PHQ-8 (depressive symptoms) Median (IQR) |
5·3 ± 4·5 5 (2, 8) |
| GAD-7 (anxiety) Median (IQR) |
4·3 ± 4·4 3 (1, 6) |
| General health characteristics | |
| Number of comorbid conditions Median (IQR) |
2·0 ± 1·7 2 (1,3) |
| Obesity (BMI ≥30) | 25 (63) |
| SLE-related | |
| SLE disease duration (years) | 22·4 ± 10·7 |
| SLE disease damage (BILD) Median (IQR) |
2·5 ± 2·4 1 (0, 3) |
| Medications | |
| High-dose glucocorticoids | 14 (35) |
| Hydroxychloroquine | 65 (163) |
| Immunosuppressives | 51 (129) |
*
Race and ethnicity categories are mutually exclusive.
BILD= Brief Index of Lupus Damage: BMI= body mass index; GAD-7= General Anxiety Disorder-7; PHQ-8= Patient Health Questionnaire-8; PROMIS= Patient-reported Outcomes Measurement Information System; SLE= systemic lupus erythematosus